Abuse-deterrent opioid formulations: Are they a pipe dream?

Current Rheumatology Reports

Volumn 10, Issue 1, 2008, Pages 11-18

  Katz, Nathaniel ^a  

^a Analgesic Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; CODEINE; DEXAMPHETAMINE; DIAMORPHINE; FENTANYL; HYDROCODONE; LISDEXAMFETAMINE; METHYLPHENIDATE; MORPHINE; MU OPIATE RECEPTOR AGONIST; NALOXONE; NICOTINIC ACID; NRP 290; OPIATE; OXYCODONE; PENTAZOCINE; PRODRUG; TALWIN NX; TILIDINE; TRAMADOL; UNCLASSIFIED DRUG; NARCOTIC ANALGESIC AGENT;

ABUSE DETERRENT OPIOID FORMULATION; ACCIDENTAL PEDIATRIC INGESTION; ANALGESIA; ATTENTION DEFICIT DISORDER; BIOTRANSFORMATION; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG COST; DRUG DEPENDENCE; DRUG DESIGN; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG FORMULATION; DRUG MISUSE; DRUG RELEASE; HUMAN; INGESTION; INTOXICATION; INTRAVENOUS DRUG ABUSE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; OPIATE ADDICTION; PRESCRIPTION; PUBLIC HEALTH; REVIEW; SUICIDE ATTEMPT; CHEMISTRY; METHODOLOGY; PAIN;

ANALGESICS, OPIOID; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; HUMANS; OPIOID-RELATED DISORDERS; PAIN;

EID: 44949084623     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-008-0003-z     Document Type: Review

References (43)

1. Katz NP, Adams EH, Benneyan JC, et al.: Foundations of opioid risk management. Clin J Pain 2007, 23:103-118.
2. Savage S, Covington EC, Heit HA, et al.: Definitions related to the use of opioids for the treatment of pain. American Academy of Pain Medicine, American Pain Society, and American Society of Addiction Medicine, 2007. Available at http://www.ampainsoc.org/advocacy/ opioids2.htm. Accessed November 28, 2007.
3. Katz NP, Adams EH, Chilcoat H, et al.: Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain 2007, 23:648-660.
4. Substance Abuse and Mental Health Services Administration: Results from the 2006 National Survey on Drug Use and Health: National Findings. (Office of Applied Studies, NSDUH Series H-32, DHHS Publication No. SMA 07-4293). Rockville, MD: Department of Health and Human Services; 2007.
5. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4 edn, text revision. Washington, DC: American Psychiatric Association; 2000.
6. O'Brien CP, Volkow N, Li TK: What's in a word? Addiction vs. dependence in DSM-V. Am J Psychiatry 2006, 163:764-765.
7. Hays LR: A profile of OxyContin addiction. J Addict Dis 2004, 23:1-9.
8. White AG, Birnbaum HG, Mareva MN, et al.: Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm 2005, 11:469-479.
9. Compton WM, Volkow ND: Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 2006, 83(Suppl 1):S4-7.
10. Marsch LA, Bickel WK, Badger GJ, et al.: Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J Pharmacol Exp Ther 2001, 299:1056-1065.
11. Rosenblum A, Parrino M, Schnoll SH, et al.: Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend 2007, 90:64-71.
12. Butler S, Budman S, Villapiano A, et al.: The NAVIPPRO System: new data on the feasibility of real-time, product specific opioid surveillance. Presented at the American Pain Society Annual Meeting. Washington, DC; May 5-7, 2007.
13. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE: Monitoring the future national results on adolescent drug use: overview of key findings, 2006. (NIH Publication No. 07-6202). Bethesda, MD: National Institute on Drug Abuse; 2007.
14. Watson WA, Litovitz TL, Rodgers GC Jr, et al.: 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2005, 23:589-666.
15. Substance Abuse and Mental Health Services Administration, Office of Applied Studies: Drug Abuse Warning Network, 2005: National estimates of drug-related emergency department visits. (DAWN Series D-29, DHHS Publication No. SMA 07-4256.) Rockville, MD: Department of Health and Human Services; 2007.
16. Passik SD, Kirsh KL, Donaghy KB, Portenoy RK: Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuse. Clin J Pain 2006, 22:173-181.
17. Paulozzi LJ, Ryan GW: Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med 2006, 31:506-511.
18. Substance Abuse and Mental Health Services Administration, Office of Applied Studies: Drug Abuse Warning Network, 2003: area profiles of drug-related mortality. (DAWN Series D-27, DHHS Publication No. SMA 05-4023.) Rockville, MD: Department of Health and Human Services; 2005.
19. Substance Abuse and Mental Health Services Administration, Office of Applied Studies: Disposition of emergency department visits for drug-related suicide attempts by adolescents: 2004. The New DAWN Report. Issue 6. Rockville, MD: Department of Health and Human Services; 2006.
20. Booth M: Opium: A History. New York: St. Martins Press; 1996.
21. Fudala PJ, Johnson RE: Development of opioid formulations with limited diversion and abuse potential. Drug Alcohol Depend 2006, 83(Suppl 1):S40-47.
22. Katz NP, Buse DC, Budman SH, et al.: Development and preliminary experience with an ease of extractability rating system for prescription opioids. Drug Dev Ind Pharm 2006, 32:727-746.
23. Cone EJ: Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet. Drug Alcohol Depend 2006, 83(Suppl 1):S31-39.
24. Webster LR: PTI-821: sustained-release oxycodone using gel-cap technology. Expert Opin Investig Drugs 2007, 16:359-366.
25. Bartholomaeus J, Arkenau E, Ashworth JB: A new technology to increase the mechanical stability of matrix tablets to prevent abuse by crushing or chewing. Presented at the College of Problems in Drug Dependency. Bethesda, MD; April 19-20, 2005.
26. Collegium Pharmaceutical: Central nervous system. Available at http://www.collegiumpharma.com/products/cns.html. Accessed November 28, 2007.
27. Parasrampuria DA, Schoedel KA, Schuller R, et al.: Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. J Clin Psychopharmacol 2007, 27:459-467.
28. Teter CJ, McCabe SE, LaGrange K, et al.: Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy 2006, 26:1501-1510.
29. Lahmeyer HW, Craig RJ: Pentazocine-naloxone: another "addiction-proof" drug of abuse. Int J Addict 1987, 22:1163-1166.
30. Alho H, Sinclair D, Vuori E, Holopainen A: Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007, 88:75-78.
31. US Food and Drug Administration, Center for Drug Evaluation and Research: Subutex and Suboxone: questions and answers. Available at http://www.fda.gov/cder/drug/infopage/subutex_suboxone/subutex-qa.htm. Accessed November 28, 2007.
32. Katz N, Sun S, Fox L, et al.: Treatment of osteoarthritis pain with extended-release morphine sulfate plus sequestered naltrexone ASA 2007 Annual Meeting [abstract #652984]. Presented at the American Society of Anesthesiologists. San Francisco, CA; October 15, 2007.
33. Elite Pharmaceuticals Inc.: Home page. Available at www.elitepharma.com. Accessed November 28, 2007.
34. Woolf CJ, Hashmi M: Use and abuse of opioid analgesics: potential methods to prevent and deter non-medical consumption of prescription opioids. Curr Opin Investig Drugs 2004, 5:61-66.
35. Gershell L, Goater JJ: From the analyst's couch: making gains in pain. Nat Rev Drug Discov 2006, 5:889-890.
36. Acura Pharmaceuticals Inc.: Home page. Available at http://www.acurapharm.com. Accessed November 28, 2007.
37. Vyvanse [package insert]. Hampshire, UK: Shire Pharmaceuticals; 2007.
38. Rosenblum A, Parrino M, Schnoll SH, et al.: Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend 2007, 90:64-71.
39. Butler SF, Benoit CM, Budman SH, et al.: Development and validation of an opioid attractiveness scale: a novel measure of the attractiveness of opioid products to potential abusers. Harm Reduct J 2006, 3:5.
40. Bell J, White J, Saunders J, et al.: PROBUPHINE (buprenorphine implant) provides sustained serum buprenorphine concentrations and long-term control of withdrawal symptoms and cravings [poster]. Presented at the College on Problems of Drug Dependence 66th Annual Scientific Meeting. San Juan, Puerto Rico; June 12-17, 2004.
41. Sobel BF, Sigmon SC, Walsh SL, et al.: Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification. Drug Alcohol Depend 2004, 73:11-22.
42. Katz N, Fanciullo GJ: Role of urine toxicology testing in the management of chronic opioid therapy. Clin J Pain 2002, 18(4 Suppl):S76-82.
43. Ives TJ, Chelminski PR, Hammett-Stabler CA, et al.: Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res 2006, 6:46.